India, Sept. 28 -- Silexion Therapeutics Corp. (SLXN) announced positive findings from an ongoing translational study evaluating the cellular uptake and gene-silencing mechanism of SIL204, its lead RNA interference (RNAi) candidate for KRAS-driven cancers.
The study demonstrated that SIL204 can utilize naturally occurring circulating lipoproteins to facilitate intracellular delivery and drive potent, dose-dependent knockdown of mutant KRAS oncogene expression in cancer cells.
In a carrier-free, non-transfection assay, human KRAS-driven cancer cells treated with SIL204 showed robust, dose-dependent gene silencing in the presence of physiological serum lipids.
Depletion of serum lipids significantly reduced gene-knockdown efficiency (P<0.0...